[
johnson & johnson
]
EU medicine regulator assessing Covid-19 vaccines affected by cyberattack
By Agence France-Presse | Posted by Shankhyaneel Sarkar | The Hague, Netherlands
UPDATED ON DEC 10, 2020 03:54 AM IST
Pfizer and BioNTech said documents relating to its vaccine candidate had been accessed but that “no systems have been breached in connection with this incident.”
North Korea-linked hackers targeted J&J, Novavax in hunt for Covid-19 research
By Reuters | Posted by Srivatsan K C | Washington/London
UPDATED ON DEC 02, 2020 08:20 PM IST
Four people who have investigated the attacks said the spate of hacking attempts began in September, and used web domains mimicking online login portals to try and trick staff at the targeted organisations into revealing their passwords.
Indonesian women’s sexual abuse and rape threats in palm oil fields linked to top beauty brands
By Associated Press | Posted by Zarafshan Shiraz | Sumatra, Indonesia
UPDATED ON NOV 19, 2020 12:37 PM IST
A comprehensive investigation focusing on the brutal treatment of women in the production of palm oil in Indonesia, has exposed not only sexual abuse ranging from verbal harassment and threats to rape but also human trafficking, child labour and outright slavery.
Aspen agrees to make Johnson & Johnson Covid-19 vaccine in South Africa
By Bloomberg| Posted by: Harshit Sabarwal
PUBLISHED ON NOV 02, 2020 04:40 PM IST
Africa’s biggest drugmaker has the capacity to produce 300 million doses a year at the plant in Port Elizabeth if the shot is approved, the company said in a statement on Monday. J&J’s experimental inoculation against the virus that’s swept the world this year is still in clinical trials, after a brief pause last month after a patient became sick.
Johnson & Johnson plans to test its Covid-19 vaccine in ages 12-18 soon
By Reuters | Posted by Kanishka Sarkar | New York
UPDATED ON OCT 31, 2020 06:30 AM IST
J&J started testing the vaccine in adults in a 60,000-volunteer Phase III study in late September. It had to pause the trial earlier this month because of a serious medical event in one participant. The study resumed last week.
Military will be distributing vaccine, says Donald Trump, announcement in weeks
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON OCT 23, 2020 07:51 AM IST
“We can’t keep this country close. This is a massive economy. People are going into depression. The cure can’t be worse than the problem,” Trump said.
Vaccines against Covid-19 may not need to be administered annually: WHO Official
By Asian News International | Moscow
PUBLISHED ON OCT 17, 2020 03:03 PM IST
The RDIF is producing the Sputnik V vaccine in conjunction with its developer, the Gamaleya Research Institute of Epidemiology and Microbiology.
Pfizer, BioNTech vaccine trial remains on track, says CEO
By Bloomberg| Posted by Susmita Pakrasi | Bloomberg
PUBLISHED ON OCT 15, 2020 02:04 PM IST
Pfizer and BioNTech chose their candidate from a slate of four contenders, all of which relied on messenger RNA technology designed to teach the body’s cells to become vaccine factories in their own right.
Covid-19 vaccine tracker: Bharat Biotech’s new strategy, Russia’s nod to 2nd vaccine. All you need to know
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON OCT 14, 2020 09:46 PM IST
The results of Bharat Biotech’s phase 2 clinical trial will be known by November.
Covid-19: What you need to know today
By R Sukumar | Hindustan Times, New Delhi
UPDATED ON OCT 14, 2020 04:56 AM IST
Pauses, and even holds, are common in the vaccine development process. But this isn’t just any ordinary vaccine. It is a vaccine for the coronavirus disease, which has infected 38 million and killed almost 1.1 million people
AstraZeneca and Johnson & Johnson: 2 major Covid-19 vaccine trial halts the world witnessed
By hindustantimes.com | Edited by Prashasti Singh | Hindustan Times, New Delhi
UPDATED ON OCT 13, 2020 12:21 PM IST
Accidents and other so-called adverse events “are an expected part of any clinical study, especially large studies,” the company said in the statement, adding that its physicians and a safety monitoring panel would try to determine the reason behind the illness, reported news agency Associated Press.
Johnson & Johnson confirms Covid-19 vaccine trial paused on safety event
By Bloomberg | Posted by Kanishka Sarkar
UPDATED ON OCT 13, 2020 07:14 AM IST
News of the halt comes after AstraZeneca Plc temporarily stopped tests of its vaccine after a trial participant fell ill. That study has resumed in a number of countries but remains halted in the US.
J&J CEO Gorsky says Covid shows need for global health security
By Bloomberg| Posted by Susmita Pakrasi | Bloomberg
PUBLISHED ON OCT 04, 2020 08:38 AM IST
When asked by Carlyle Group Inc. co-founder Rubenstein if the White House and U.S. health agencies should have approached the pandemic differently, Gorsky said, “almost all of us have underestimated the dramatic impact of this outbreak.”
Lonza confident of 2020 target for Moderna Covid-19 vaccine supply
By Reuters| Posted by Susmita Pakrasi | Reuters
PUBLISHED ON SEP 30, 2020 09:17 AM IST
New production lines at Lonza’s site in Portsmouth, New Hampshire, aim to start making vaccine ingredients in November, while three lines in Visp, deep in a valley in the Swiss Alps - to supply 300 million vaccine doses annually - should begin delivering by December.
Johnson & Johnson Covid-19 vaccine produces strong immune response in early trial
By Reuters | Posted by Meenakshi Ray | Reuters
UPDATED ON SEP 26, 2020 06:08 PM IST
The vaccine, called Ad26.COV2.S, was equally well-tolerated at two different doses, the results showed. A single shot, versus a rival two-dose approach being tested by Moderna Inc and Pfizer Inc, could simplify distribution of the vaccine.
Covid-19: What you need to know today
By R Sukumar | Hindustan Times, New Delhi
UPDATED ON SEP 25, 2020 02:40 AM IST
All four companies — Pfizer, Moderna, AstraZeneca, and Johnson & Johnson — are also signatories to a pledge to ensure “high ethical standards and sound scientific principles”, and to not seek regulatory approval for their vaccines till clinical trials on tens of thousands of individuals show them (the vaccines) to be effective and safe.
Covid-19 vaccine: When will US get its first vaccine?
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON SEP 24, 2020 09:05 AM IST
Pfizer would know whether their vaccine candidate is effective by end of October,
Covid-19 vaccine: Johnson & Johnson begins Phase-3 trial with 60k people
By Agence France-Presse | Washington
UPDATED ON SEP 24, 2020 06:48 AM IST
With the move, J&J becomes the tenth maker globally to conduct a Phase 3 trial against Covid-19, and the fourth in the US.
Explainer: World Health Organization’s struggle for a global Covid-19 vaccine plan
By Reuters | Posted by Kanishka Sarkar
UPDATED ON AUG 19, 2020 07:22 AM IST
The WHO has expressed concern that wealthier countries hoarding vaccines for their own citizens could impede efforts to end the Covid-19 pandemic.
Britain lines up more potential Covid-19 vaccine supplies with J&J, Novavax deals
By Reuters | Posted by Kanishka Sarkar | London
UPDATED ON AUG 15, 2020 02:57 PM IST
Britain said both Covid-19 vaccines could be available by the middle of next year for priority groups, such as such as frontline health and social care workers, ethnic minorities, adults with serious diseases, and the elderly.
J&J starts human study of Covid-19 vaccine after promising monkey data
By Reuters | Posted by Shivani Kumar
UPDATED ON JUL 31, 2020 08:07 AM IST
The drugmaker said it had started early-stage human trials in the United States and Belgium and would test its vaccine candidate in more than 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.
J&J in talks with Japan, Gates Foundation to lock in deals on Covid-19 vaccine
By Reuters| Posted by Susmita Pakrasi | Reuters
PUBLISHED ON JUL 16, 2020 10:33 PM IST
More than a hundred vaccines are under development to try and stop the Covid-19 pandemic, and drugmakers including J&J are working to ramp up supply for their vaccines in the face of unprecedented demand.
AstraZeneca to make billion Covid vaccine doses if tests succeed
By Reuters | Reuters
PUBLISHED ON MAY 21, 2020 02:06 PM IST
The British drugmaker said it had signed the first agreements to supply at least 400 million doses of the vaccine, which it is developing with Oxford University.
Johnson & Johnson to stop selling talc-based baby powder in US and Canada
By Reuters | Posted by Anubha Rohatgi | Reuters
UPDATED ON MAY 20, 2020 06:28 AM IST
J&J faces more than 16,000 lawsuits from consumers claiming its talc products, including Johnson’s Baby Powder, caused their cancer. The majority are pending before a US district judge in New Jersey.
US court slashes $8 billion Johnson & Johnson damages over drug side effect
By Agence France-Presse | New York
PUBLISHED ON JAN 18, 2020 07:06 AM IST
Johnson & Johnson said that although the court “appropriately reduced the excessive punitive damages award, we will continue to move ahead with an appeal of this verdict.”
No link between talcum powder and ovarian cancer, finds study
By HT Correspondent | Agence France-Presse, Washington
UPDATED ON JAN 08, 2020 02:54 PM IST
The paper appeared in the influential Journal of the American Medical Association (JAMA), which also published an editorial praising the research methods and calling the findings “overall reassuring.”
Johnson & Johnson ordered to pay $8 billion over drug side effect
By Agence France-Presse | New York
UPDATED ON OCT 09, 2019 12:09 PM IST
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray told the Philadelphia court that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, had made him grow breasts.
Women in STEM2D Scholars Award: Apply now, winners to get $150,000 each
By HT Correspondent | Hindustan Times, New Delhi
UPDATED ON SEP 03, 2019 06:59 PM IST
Johnson & Johnson has invited nominations for its 2020 Women in STEM 2 D (WiSTEM 2D) Scholars Award. Each recipient will receive $150,000 — $50,000 each year for three years — and three years of mentorship from leaders at Johnson & Johnson.
Johnson & Johnson liable for $572 m in Oklahoma opioid epidemic trial
By Reuters | Oklahoma
UPDATED ON AUG 27, 2019 12:13 PM IST
The state’s attorney general had filed the lawsuit, seeking $17 billion to address the impact of the drug crisis on Oklahoma. It had been considered a bellwether for other litigation nationwide over the opioid epidemic.
AIIMS to start registry of all orthopaedic implant surgeries to track outcomes
By Rhythma Kaul | Hindustan Times, New Delhi
PUBLISHED ON APR 11, 2019 02:33 PM IST
The AIIMS orthopaedic department is in the process of submitting a proposal to the ICMR in this regard so that it is executed as an Icmr-supported project that can also be replicated in other regions.
- 1
- 2
- ...